Oruka Therapeutics, Inc. Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure
Oruka Therapeutics, Inc. (ORKA) reported Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure of $0 for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-08-11.
Discontinued › Notes
us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure · last filed 2015-08-11
- Oruka Therapeutics, Inc. concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2015-06-30 was $0.00.
- Oruka Therapeutics, Inc. concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2015-03-31 was $0.00.
- Oruka Therapeutics, Inc. concentration risk, credit risk, financial instrument, maximum exposure for fiscal 2014 was $0.00.
| Period end | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 3 month | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 6 month | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 12 month |
|---|---|---|---|
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $0.00 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-12 | ||
| 2014-12-31 | $0.00 10-K · filed 2015-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |